Re-exposure of a PD-1 inhibitor after previous immune-related adverse events
Background: Programmed cell death protein (ligand) 1 (PD-(L)1) inhibitors are well established in the treatment of dermatological tumors. Mostly, they are well tolerated, but in about 9-21% of patients, grade 3/4 immune-related adverse events (irAEs) occur. As treatment options are limited, it is of...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Article (Journal) |
| Lenguaje: | inglés |
| Publicado: |
24 March 2026
|
| In: |
Current oncology
Year: 2026, Volumen: 33, Número: 4, Pages: 1-12 |
| ISSN: | 1718-7729 |
| DOI: | 10.3390/curroncol33040180 |
| Acceso en línea: | Verlag, kostenfrei, Volltext: https://doi.org/10.3390/curroncol33040180 Verlag, kostenfrei, Volltext: https://www.mdpi.com/1718-7729/33/4/180 
|
| Notas de Autor: | Jana Burghaus-Zhang, Carsten Schulz, Egle Ramelyte, Joanna Mangana, Deniz Özistanbullu, Johannes Kleemann, Alexander Enk and Jessica C. Hassel |
Search Result 1